natgillin/translations-raw huggingface dataset:
The Phase 3 study excluded patients who were refractory to lenalidomide or proteasome inhibitors and patients who received more than three prior therapies. 
Ispitivanje faze 3 isključilo je bolesnike koji su bili refraktorni na lenalidomid ili inhibitore proteasoma, te bolesnike koji su primili više od tri prethodne terapije.
NINLARO may affect your ability to drive or use machines. 
NINLARO može utjecati na sposobnost upravljanja vozilima ili rada sa strojevima.
If you are a woman of childbearing potential or a man who can father a child, you must use effective contraception during and for 90 days after treatment. 
Ako ste žena koja može zanijeti ili muškarac koji može začeti dijete morate koristiti djelotvorne mjere kontracepcije tijekom i barem 90 dana nakon terapije.
Placebo + Lenalidomide and Dexamethasone (N = 362) 
placebo + lenalidomid i deksametazon (N = 362)
The mean AUC was 35% higher in Asian patients; however, there was overlap in the AUC of ixazomib across White and Asian patients. 
Srednja vrijednost AUC-a bila je za 35% viša u azijskih bolesnika; međutim, postojalo je preklapanje u AUC iksazomiba u bolesnika bijele i azijske rase.
Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. 
Unutar svake klase organskih sustava, nuspojave su poredane po učestalosti, pri čemu su najčešće navedene na prvom mjestu.
What NINLARO is NINLARO is a cancer medicine that contains ixazomib, a ‘proteasome inhibitor'. 
Što je NINLARO NINLARO je lijek protiv raka koji sadrži iksazomib, „inhibitor proteasoma“.
A randomised, double-blind, placebo-controlled Phase 3 study was conducted in China (N=115) with a similar study design and eligibility criteria. 
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje faze 3 provedeno je u Kini (N = 115), sa sličnim dizajnom i uključnim kriterijima.
Tell doctor right away if you or your partner becomes pregnant while receiving NINLARO. 
Odmah obavijestite svog liječnika ako zatrudnite, ili ako Vaša partnerica zatrudni, dok primate NINLARO.
Nervous system disorders Peripheral neuropathies* Very common 
Poremećaji živčanog sustava Periferne neuropatije* Vrlo često
Do not drive or operate machines if you have these side effects. 
Nemojte upravljati vozilima niti raditi sa strojevima ako imate te nuspojave.
Concomitant medicinal products, such as antiemetic, antiviral, and antihistamine medicinal products were given to patients at the physician's discretion as prophylaxis and/or management of symptoms. 
Konkomitantni lijekovi poput antiemetika, antivirusnih lijekova i antihistaminika davani su bolesnicima prema odluci liječnika kao profilaksa i/ili simptomatska terapija.
At the primary analysis (median follow up of 14.7 months and a median of 13 cycles), PFS was statistically significantly different between the treatment arms. 
Na primarnoj analizi (medijan praćenja do 14,7 mjeseci, a medijan broja ciklusa 13), PFS rezultati bili su statistički značajno različiti između liječenih skupina.
Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses under physiological conditions to its biologically active form, ixazomib. 
Iksazomibcitrat je predlijek koji se u fiziološkim uvjetima brzo hidrolizira u svoj biološki aktivni oblik, iksazomib.
Twenty three percent of patients had light chain disease and 12% of patients had measurable disease by free light chain assay only. 
Dvadeset i tri posto bolesnika imalo je bolest lakih lanaca, a 12% bolesnika imalo je bolest koja se mogla dokazati samo mjerenjem slobodnih lakih lanaca.
Unchanged ixazomib accounted for < 3.5% of the administered dose recovered in urine. 
Nepromijenjeni iksazomib sačinjavao je < 3,5% primijenjene doze pronađene u mokraći.
What you need to know before you take NINLARO 
Što morate znati prije nego počnete uzimati NINLARO
In multi-cycle repeated-dose toxicity studies conducted in rats and dogs, the principal target organs included the gastrointestinal tract, lymphoid tissues, and the nervous system. 
U više ciklusa ispitivanja toksičnosti ponovljene doze provedenih na štakorima i psima, glavni ciljni organi uključivali su gastrointestinalni trakt, limfoidna tkiva i živčani sustav.
Ixazomib caused embryo-foetal toxicity in pregnant rats and rabbits only at maternally toxic doses and at exposures that were slightly higher than those observed in patients receiving the recommended dose. 
Iksazomib je uzrokovao embriofetalnu toksičnost u gravidnih ženki štakora i kunića samo pri maternalno toksičnim dozama i pri izloženostima koje su bile nešto više od onih uočenih u bolesnika koji su primali preporučenu dozu.
Studies of fertility and early embryonic development and pre- and post-natal toxicology were not conducted with ixazomib, but evaluation of reproductive tissues was conducted in the general toxicity studies. 
Ispitivanja plodnosti i ranog embrionalnog razvoja kao i pre- i postnatalna toksikologija nisu provedena s iksazomibom, ali je procjena reproduktivnih tkiva provedena u ispitivanjima opće toksičnosti.
When ixazomib is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered. 
Kada se iksazomib primjenjuje zajedno s deksametazonom, za koji je poznato da je slabi do umjereno jaki induktor CYP3A4 kao i drugih enzima i prijenosnika, potrebno je uzeti u obzir rizik od smanjene djelotvornosti oralnih kontraceptiva.
Ixazomib exhibits a multi-exponential disposition profile. 
Iksazomib iskazuje multieksponencijalni profil dispozicije.
Nineteen percent had high-risk cytogenetic abnormalities (del[17], t[4;14], t[14;16]) (N=137), 10% had del(17) (N=69) and 34% had 1q amplification (1q21) (N=247). 
Devetnaest posto imalo je citogenetičke abnormalnosti visokog rizika (del[17], t[4;14], t[14;16]) N = 137), 10% del(17) (N = 69), a 34% amplifikaciju lq (1q21) (N = 247).
Patients experiencing new or worsening peripheral neuropathy may require dose modification (see section 4.2). 
U bolesnika u kojih se pojavi nova ili se pogorša postojeća periferna neuropatija može biti potrebna prilagodba doze (vidjeti dio 4.2).
Women using hormonal contraceptives should additionally use a barrier method of contraception. 
Žene koje koriste hormonske kontraceptive trebaju dodatno koristiti mehaničku metodu kontracepcije.
After oral administration, peak plasma concentrations of ixazomib were achieved at approximately one hour after dosing. 
Nakon peroralne primjene vršne koncentracije iksazomiba u plazmi postignute su približno sat vremena nakon doziranja.
Clinical data is limited but doses up to 12 mg have been reported in the randomised controlled trial. 
Klinički podaci su ograničeni, ali su u randomiziranom kontroliranom kliničkom ispitivanju zabilježene doze do 12 mg.
Male and female patients who are able to have children must use effective contraceptive measures during and for 90 days following treatment. 
Muški i ženski bolesnici reproduktivne dobi moraju koristiti djelotvorne kontracepcijske mjere tijekom i 90 dana nakon liječenja.
Metabolism by multiple CYP enzymes and non-CYP proteins is expected to be the major clearance mechanism for ixazomib. 
Očekuje se da će metabolizam putem više CYP enzima i ne-CYP proteina biti glavni mehanizam eliminacije za iksazomib.
Less than 1% of patients in both regimens had a platelet count ≤ 5,000/mm3 during treatment. 
Manje od 1% bolesnika u oba režima imalo je tijekom liječenja broj trombocita ≤ 5000/mm3.
Women of childbearing potential must use highly effective contraception while taking ixazomib and for 90 days after stopping treatment (see sections 4.5 and 4.6). 
Žene u reproduktivnoj dobi moraju koristiti visoko djelotvornu kontracepciju za vrijeme primjene iksazomiba i tijekom 90 dana nakon prekida terapije (vidjeti dio 4.5 i 4.6).
There are no data for the use of ixazomib in pregnant women. 
Nema podataka o primjeni iksazomiba u trudnica.
PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, altered consciousness, and visual disturbances. 
PRES je rijetki, reverzibilni neurološki poremećaj koje se manifestira napadajima, hipertenzijom, glavoboljom, promijenjenim stanjem svijesti, te smetnjama vida.
If a patient vomits after taking a dose, the patient should not repeat the dose but should resume dosing at the time of the next scheduled dose. 
Ako bolesnik povraća nakon primjene doze, ne smije ponovno uzeti dozu već mora nastaviti doziranje u vrijeme sljedeće predviđene doze.
Following oral administration, a tissue distribution study in rats revealed that the brain and spinal cord were amongst the tissues with the lowest levels, suggesting that the penetration of ixazomib through the blood-brain barrier appears to be limited. 
Nakon peroralne primjene, ispitivanje distribucije po tkivima u štakora otkrilo je da su mozak i kralježnička moždina među tkivima s najnižom razinom lijeka što ukazuje na to da je penetracija iksazomiba kroz krvno-moždanu barijeru ograničena.
Ninety three percent of patients had an ECOG performance status of 0-1 and 12% had baseline ISS stage III disease (N=90). 
Devedeset i tri posto bolesnika imalo je ECOG funkcionalni status od 0-1, a 12% imalo je početni ISS stadij III bolesti (N = 90).
Do not use this medicine after the expiry date which is stated on the blister, wallet and carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru, ovitku i kutiji iza oznake EXP.
Therefore, women using oral hormonal contraceptives should additionally use a barrier method of contraception. 
Stoga žene koje koriste oralne hormonske kontraceptive trebaju dodatno koristiti mehaničku metodu kontracepcije.
Treatment continued until disease progression or unacceptable toxicities. 
Liječenje je nastavljeno do napredovanja bolesti ili do neprihvatljivih toksičnosti.
The improvement in PFS in the ixazomib regimen was supported by improvements in overall response rate. 
Poboljšanje PFS-a u režimu s iksazomibom potkrijepljeno je poboljšanjem stope ukupnog odgovora.
You may feel tired and dizzy while taking NINLARO. 
Možete osjećati umor i omaglicu dok uzimate NINLARO.
Strong inducers may reduce the efficacy of ixazomib, therefore the concomitant use of strong CYP3A inducers such as carbamazepine, phenytoin, rifampicin and St. John's Wort (Hypericum perforatum), should be avoided (see sections 4.5 and 5.2). 
Jaki induktori mogu smanjiti djelotvornost iksazomiba pa stoga treba izbjegavati istodobnu primjenu jakih induktora CYP3A poput karbamazepina, fenitoina, rifampicina i gospine trave (Hypericum perforatum), (vidjeti dijelove 4.5 i 5.2).
The conditions of the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential. 
Programa sprečavanja trudnoće za lenalidomid, osim ako postoji pouzdan dokaz da bolesnica ne može zanijeti.
In the 9-month study (10 cycles) in dogs orally administered with a dosing schedule mimicking the clinical regimen (28-day cycle), microscopic neuronal effects were generally minimal in nature and only observed at 0.2 mg/kg (4 mg/m2). 
U devetomjesečnom ispitivanju (10 ciklusa) u pasa kojima je peroralno primijenjen režim koji oponaša klinički režim (28-dnevni ciklus), mikroskopski učinci na neuronima bili su općenito minimalne naravi te uočeni samo pri dozi od 0,2 mg/kg (4 mg/m2).
The primary endpoint was progression-free survival (PFS) according to the 2011 International Myeloma Working Group (IMWG) Consensus Uniform Response Criteria as assessed by a blinded independent review committee (IRC) based on central laboratory results. 
Primarna mjera ishoda bila je preživljenje bez napredovanja bolesti (engl. progression free survival, PFS) u skladu s konsenzusom Međunarodne radne skupine za mijelom iz 2011. godine o uniformnim kriterijima odgovora i prema procjeni nezavisnog povjerenstva za procjenu koje je pregledalo maskirane rezultate središnjeg laboratorija.
In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines: carbamazepine, phenytoin, rifampicin and St. John's wort (Hypericum perforatum). 
Posebno je važno da obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate ijedan od sljedećih lijekova: karbamazepin, fenitoin, rifampicin i gospinu travu (Hypericum perforatum).
Outside of the Phase 3 study, the following serious adverse reactions were rarely reported: acute febrile neutrophilic dermatosis (Sweet's syndrome), Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome and thrombotic thrombocytopenic purpura. 
Izvan ispitivanja faze 3 rijetko su zabilježene sljedeće ozbiljne nuspojave: akutna febrilna neutrofilna dermatoza (Sweetov sindrom), Stevens-Johnsonov sindrom, transverzalni mijelitis, sindrom posteriorne reverzibilne encefalopatije, sindrom lize tumora i trombotička trombocitopenična purpura.
A hazard ratio less than 1 indicates an advantage for the ixazomib regimen. 
Omjer hazarda manji od 1 ukazuje na prednost terapijskog režima iksazomibom.
It is unknown whether ixazomib or its metabolites are excreted in human milk. 
Nije poznato izlučuju li se iksazomib ili njegovi metaboliti u majčino mlijeko u ljudi.
Patients received one to three prior therapies (median of 1) including prior treatment with bortezomib (69%), carfilzomib (<1%), thalidomide (45%), lenalidomide (12%), melphalan (81%). 
Bolesnici su primili jednu do 3 prethodne terapije (medijan 1) uključujući prethodnu terapiju bortezomibom (69%), karfilzomibom (< 1%), talidomidom (45%), lenalidomidom (12%), melfalanom (81%).
Serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhoea (2%). 
Ozbiljne nuspojave prijavljene u ≥ 2% bolesnika uključivale su trombocitopeniju (2%) i dijareju (2%).
Ixazomib was positive in an in vitro clastogenicity test in human peripheral blood lymphocytes. 
Iksazomib je bio pozitivan u in vitro testu klastogenosti na limfocitima periferne ljudske krvi.
Days 23 to 28 
23. do 28. dan
Non-clinical safety pharmacology studies both in vitro (on hERG channels) and in vivo (in telemetered dogs following single oral administration) demonstrated no effects of ixazomib on cardiovascular or respiratory functions at AUC more than 8-fold higher than the clinical value. 
Neklinička ispitivanja sigurnosne farmakologije in vitro (na hERG kanalima) te in vivo (u telemetrijski praćenih pasa nakon peroralne primjene pojedinačne doze) nisu dokazala učinke iksazomiba na kardiovaskularne ili respiratorne funkcije pri AUC-u 8 puta većem od kliničke vrijednosti.
Treatment with ixazomib in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity beyond 24 cycles are limited (see section 5.1). 
Liječenje iksazomibom u kombinaciji s lenalidomidom i deksametazonom dulje od 24 ciklusa treba se temeljiti na procjeni odnosa koristi i rizika za svakog pojedinog bolesnika, jer su podaci o podnošljivosti i toksičnosti za više od 24 ciklusa ograničeni (vidjeti dio 5.1).
Ixazomib is 99% bound to plasma proteins and distributes into red blood cells with a blood-to-plasma AUC ratio of 10. 
Iksazomib je 99% vezan za proteine plazme i distribuira se u eritrocite s omjerom AUC krv/plazma od 10.
Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5 activity or corresponding immunoreactive protein levels. 
Iksazomib nije inducirao aktivnost CYP1A2, CYP2B6 i CYP3A4/5 ili razine odgovarajućih imunoreaktivnih proteina.
• severe skin rashes such as red to purple bumps (Sweet's syndrome) or rash with skin peeling and mouth sores (Stevens-Johnson syndrome) 
• teški kožni osipi poput crvenih do ljubičastih plakova (Sweetov sindrom) ili osip s guljenjem kože i ranama u ustima (Stevens-Johnsonov sindrom)
• cold-like symptoms (upper respiratory tract infection) 
• simptomi nalik prehladi (infekcija gornjeg dišnog sustava)
Many of the patients enrolled in the study had advanced disease with Durie-Salmon Stage III (69%) at initial diagnosis and a treatment history of receiving at least 2 prior therapies (60%) and being thalidomide refractory (63%). 
Mnogi bolesnici uključeni u ispitivanje imali su uznapredovalu bolest Durie-Salmon stadija III (69%) pri početnoj dijagnozi i povijest liječenja u kojem su primili najmanje 2 prethodne terapije (60%), uz refraktornost na talidomid (63%).
Patients included in studies with ixazomib who received antiviral prophylaxis had a lower incidence of herpes zoster infection compared to patients who did not receive prophylaxis. 
Bolesnici uključeni u ispitivanja iksazomiba koji su primali antivirusnu profilaksu imali su nižu incidenciju infekcije herpes zosterom u usporedbi s bolesnicima koji nisu primili profilaksu.
If you have liver or kidney problems, your doctor may prescribe NINLARO capsules containing 3 mg. 
Ako imate problema s jetrom ili bubrezima, liječnik može propisati NINLARO kapsule u dozi od 3 mg.
If you are uncertain whether the condition above applies to you, talk to your doctor, pharmacist or nurse before taking NINLARO. 
Ako niste sigurni odnosi li se nešto od gore navedenog na vas, razgovarajte sa svojim liječnikom, ljekarnikom ili medicinskom sestrom prije nego uzmete lijek NINLARO.
What NINLARO is and what it is used for 
Što je NINLARO i za što se koristi
The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. 
Kombinacija iksazomiba i lenalidomida dokazala je sinergističke citotoksične učinke u staničnim linijama multiplog mijeloma.
If ixazomib is used during pregnancy or if the patient becomes pregnant while taking ixazomib, the patient should be apprised of the potential hazard to the foetus. 
Ako se iksazomib koristi tijekom trudnoće ili ako bolesnica zatrudni za vrijeme terapije iksazomibom, bolesnicu treba obavijestiti o potencijalnoj opasnosti za fetus.
After oral administration of a radiolabeled dose, 70% of total drug-related material in plasma was accounted for by ixazomib. 
Nakon peroralne primjene radiooznačene doze, 70% ukupnog materijala povezanog s lijekom u plazmi sastojalo se od iksazomiba.
Figure 1: Kaplan-Meier plot of progression-free survival in the intent-to-treat population 
Slika 1: Kaplan-Meierova krivulja preživljenja bez napredovanja bolesti u populaciji bolesnika s namjerom liječenja
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOR WALLET 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER ZA OVITAK
Closely monitor patients for disease control if coadministration with a strong CYP3A inducer cannot be avoided. 
Potrebno je pažljivo nadzirati kontrolu bolesti ako se ne može izbjeći istodobna primjena jakih induktora CYP3A.
NINLARO is used with lenalidomide (a medicine which affects how your immune system works) and dexamethasone (an anti-inflammatory medicine). 
NINLARO se primjenjuje s lenalidomidom (lijekom koji utječe na način rada imunološkog sustava) i deksametazonom (protuupalnim lijekom).
The most common adverse reactions were blurred vision (5% in the ixazomib regimen and 4% in the placebo regimen), dry eye (4% in the ixazomib regimen and 1% in the placebo regimen), conjunctivitis (5% in the ixazomib regimen and 1% in the placebo regimen) and cataract (4% in the ixazomib regimen and 5% in the placebo regimen). 
Najčešće nuspojave bile su zamućenje vida (5% u režimu s iksazomibom i 4% u režimu s placebom), suhoća oka (4% u režimu iksazomibom i 1% u režimu s placebom), konjunktivitis (5% u režimu s iksazomibom i 1% u režimu s placebom) i katarakta (4% u režimu s iksazomibom i 5% u režimu s placebom).
Thrombocytopenia can be managed with dose modifications (see section 4.2) and platelet transfusions as per standard medical guidelines. 
Trombocitopenija se može zbrinuti prilagodbama doze (vidjeti dio 4.2) i transfuzijama trombocita prema standardnim medicinskim smjernicama.
Posterior reversible encephalopathy syndrome (PRES) has occurred in patients receiving ixazomib. 
Prijavljeni su slučajevi sindroma posteriorne reverzibilne encefalopatije (engl. posterior reversibile encephalopathy syndrome, PRES) u bolesnika koji su uzimali iksazomib.
Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma. 
Liječenje mora započeti i nadzirati liječnik iskusan u liječenju multiplog mijeloma.
• Absolute neutrophil count should be ≥ 1,000/mm3 
• Apsolutni broj neutrofila treba biti ≥ 1000/mm3
Do not crush, chew or open the capsule. 
Nemojte lomiti, žvakati niti otvarati kapsulu.
Multiple myeloma is a cancer of the blood which affects a type of cell, called the plasma cell. 
Multipli mijelom je rak krvi koji zahvaća vrstu stanica, takozvane plazma stanice.
‡ORR = CR+VGPR+PR §Based on responders in the response-evaluable population 
‡ORR = CR+VGPR+PR §Na temelju bolesnika koji su reagirali na terapiju u populaciji kod koje je moguće procijeniti odgovor
Patients that changed therapies prior to disease progression were eligible for enrolment, as well as those with controlled cardiovascular conditions. 
Za uključivanje su bili primjereni bolesnici koji su prije napredovanja bolesti mijenjali terapiju, kao i oni s kontroliranim kardiovaskularnim stanjima.
Very common side effects may affect more than 1 in 10 people: 
Vrlo česte nuspojave koje se mogu javiti u više od 1 na 10 osoba:
The most common type of rash reported in both regimens was maculo-papular and macular rash. 
Najčešći tip osipa zabilježen u oba režima bili su makulopapularni i makularni osip.
*P-value is based on the stratified log-rank test. †Hazard ratio is based on a stratified Cox's proportional hazard regression model. 
†Procjena omjera hazarda temelji se na Coxovom regresijskom modelu proporcionalnog hazarda.
3 packs of 1 hard capsule. 
3 pakiranja s po 1 tvrdom kapsulom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21 November 2016 
Datum prvog odobrenja: 21. studenoga 2016.
Takeda GmbH Production Site Singen Robert Bosch Strasse 8 78224 Singen Germany 
Takeda GmbH Production SiteSingen Robert Bosch Strasse 8 78224 Singen Njemačka
Fifty seven percent of patients had undergone prior stem cell transplantation. 
Pedeset i sedam posto bolesnika podvrgnulo se prethodnoj transplantaciji matičnih stanica.
Co-administration of ixazomib with rifampicin decreased ixazomib Cmax by 54% and AUC by 74%. 
Istodobna primjena iksazomiba s rifampicinom smanjila je Cmax iksazomiba za 54% i AUC za 74%.
Takeda GmbH Takeda (Werk Singen) Robert Bosch Straße 8 78224 Singen Germany 
Takeda GmbH Takeda (Werk Singen) Robert Bosch Straße 8 78224 Singen Njemačka
• nausea, vomiting and diarrhoea 
• mučnina, povraćanje i proljev
Thrombocytopenia did not result in an increase in haemorrhagic events or platelet transfusions. 
Trombocitopenija nije uzrokovala porast u hemoragijskim događajima ili transfuzijama trombocita.
• reactivation of the chicken pox virus (shingles) that can cause a skin rash and pain (herpes zoster) 
• reaktivacija virusa vodenih kozica, što može uzrokovati kožni osip i bol (herpes zoster)
Ixazomib is not recommended during pregnancy as it can cause foetal harm when administered to a pregnant woman. 
Iksazomib se ne preporučuje tijekom trudnoće jer može uzrokovati oštećenje fetusa kada se primjenjuje kod trudnica.
At concentrations exceeding those observed clinically, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42.3%), 1A2 (26.1%), 2B6 (16.0%), 2C8 (6.0%), 2D6 (4.8%), 2C19 (4.8%) and 2C9 (< 1%). 
Pri koncentracijama koje premašuju one uočene klinički, iksazomib se metabolizira putem više CYP izooblika s procijenjenim relativnim doprinosima za 3A4 (42,3%), 1A2 (26,1%), 2B6 (16,0%), 2C8 (6,0%), 2D6 (4,8%), 2C19 (4,8%) i 2C9 (< 1%).
• skin rash that may be itchy and in a few areas or all over the body 
• kožni osip koji može svrbjeti i zahvatiti nekoliko mjesta ili cijelo tijelo
• Platelet count should be ≥ 75,000/mm3 
• Broj trombocita treba biti ≥ 75 000/mm3